Clinical Trial Update: Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial at Zhejiang Cancer Hospital is evaluating hypofractionated IMRT with temozolomide and GM-CSF for newly diagnosed glioblastoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Leukine (sargramostim)
• Temodar (Temozolomide)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Glioblastoma Multiforme | Phase 2 | Status: UNKNOWN